Revised FIGO staging system for gestational trophoblastic tumors. Recommendations regarding therapy.
OBJECTIVE
To evaluate the revised International Federation of Gynecology and Obstetrics (FIGO) staging system for gestational trophoblastic tumors (GTT) and to recommend therapy.


METHODS
Review of the literature regarding the development of the FIGO staging system, the World Health Organization (WHO) prognostic scoring system and Hammond's clinical classification for GTT plus analysis of response to single-agent chemotherapy in 546 patients treated at the New England Trophoblastic Disease Center.


RESULTS
The revised FIGO staging system appears to successfully combine anatomic staging and a prognostic clinical classification. The revised FIGO staging system reliably predicts treatment outcome and therefore can be used to help select optimal treatment protocols.


CONCLUSIONS
The revised FIGO staging system is capable of predicting patients who respond poorly to single-agent chemotherapy, appears to reliably predict outcome and therefore can be used to help select appropriate treatment protocols.
Goldstein
D P
DP
New England Trophoblastic Disease Center, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Zanten-Przybysz
I V
IV
Bernstein
M R
MR
Berkowitz
R S
RS
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000592:standards / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000592:standards / Q000627:therapeutic use*; D009367:Neoplasm Staging; D011247:Pregnancy; D011379:Prognosis; D014328:Trophoblastic Neoplasms / Q000188:drug therapy / Q000473:pathology; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000473:pathology; D014944:World Health Organization
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate